Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study.

Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. Abstract Text:

U G Ahlfors,R Rimön,B Appelberg,U Hagert,P Harma,H Katila,A Mahlanen,O P Mehtonen,H Naukkarinen,J Outakoski,

Ninety-two patients with schizophrenia were included in a double-blind multicentre parallel-group trial comparing remoxipride and haloperidol. The mean daily dose during the last week of treatment was 316 mg (range, 150-600 mg) in the remoxipride group and 8.7 mg (range, 5-20 mg) in the haloperidol group. The study period was six weeks with at least one day of washout. Both Clinical Global Impression (CGI) rating, and Brief Psychiatric Rating Scale (BPRS) total scores declined at the end of the trial compared with pretreatment values in both groups. No significant differences were found between the remoxipride and haloperidol groups with regard to the treatment outcome. Treatment-emergent extrapyramidal symptoms were statistically more frequent and more severe during haloperidol than during remoxipride treatment. Haloperidol-treated patients reported also significantly more concentration difficulties. Severe extrapyramidal side effects in the haloperidol group and clinical ineffectiveness in the remoxipride group were the most frequent reasons for premature discontinuation of treatment.

Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. Publishing Authors By Initials

UG Ahlfors,R Rimön,B Appelberg,U Hagert,P Harma,H Katila,A Mahlanen,OP Mehtonen,H Naukkarinen,J Outakoski,

For similar behavioral disciplines and activities: schizophrenic psychology research abstracts see: behavioral disciplines and activities: schizophrenic psychology research

PUBMED ID PMID:

MEDLINE DATE:

Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: Acta psychiatrica Scandinavica. Supplementum

VOLUME: 358

Page Numbers: 99-103

Journal Abbreviation:

ISSN: 0065-1591

DAY: 15

MONTH: 02

YEAR: 1990

Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370365

Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. Keywords Mesh Terms:

KEYWORDS: Schizophrenic Psychology

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. Information

Substance Name: Remoxipride

Registry Number: 80125-14-0

Grant and Affiliation Information for Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study.

AFFILIATION: Hesperia Hospital, Helsinki, Finland.

Country: DENMARK

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Psychiatr Scand Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study Related Publications

• Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study.